Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium and tiotropium + olodaterol with behavioral modification and exercise training in COPD
NL-OMON40388Phase 3Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Endurance time during ESWT at Week 8. Planned start Mar 2014; status: withdrawn.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON40388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40388.